Ind-Swift has reported results for first quarter ended June 30, 2012.
On standalone basis, the company has reported a net loss of Rs 62.90 crore for the quarter ended June 30, 2012 against net profit of Rs 15.34 crore for the corresponding period last fiscal. However, total income increased by 63.31% at Rs 392.66 crore during the quarter under review from Rs 240.43 crore in the year-ago period.
Ind-Swift is a fully integrated pharma group. The API required for the product was supplied from the USFDA and MHRA approved plant of Ind-Swif Laboratories and the formulations was manufactured and supplied from the 100% export facility of Ind-Swift located near Derabassi Punjab.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: